Cohance Lifesciences Profit & Loss Annual

BSE: - | NSE: - | ISIN: - | Sector: -
420.00 -9.45 (-2.20%)Updated : 20 May 2026
Fiscal Period2026202520242023
Period End DateMar 26Mar 25Mar 24Mar 23
Total Operating Expense 2,058.361,994.02700.00821.52
Other Net 34.0969.216.353.40
Diluted Weighted Average Shares 38.3038.4325.4625.46
Depreciation/ Amortization 187.33166.8054.5047.73
Operating Income 210.19614.48351.35518.81
Net Income 179.23487.34300.28411.29
Income Availableto Com Excl Extra Ord 179.23487.34300.28411.29
Other Operating Expenses Total 671.22547.1550.0061.91
Net Income Before Taxes 207.04642.63405.67559.73
Minority Interest 29.113.10--
Net Income After Taxes 150.12484.24300.28411.29
Income Availableto Com Incl Extra Ord 179.23487.34300.28411.29
Costof Revenue Total 662.63816.48432.62568.34
Gross Profit 1,605.921,792.02618.73771.99
Interest Inc( Exp) Net- Non- Op Total -37.24-41.0648.1037.53
Unusual Expense( Income) 29.4715.783.22-
Diluted Net Income 179.23487.34300.28411.29
Provisionfor Income Taxes 56.92158.39105.39148.44
period Type ----
Net Income Before Extra Items 179.23487.34300.28411.29
Total Revenue 2,268.552,608.501,051.351,340.33
period Length 12.0012.0012.0012.00
Revenue 2,268.552,608.501,051.351,340.33
Selling/ General/ Admin Expenses Total 507.71447.81159.66134.95
Diluted Normalized EPS 5.2412.9911.8916.16
Diluted EPS Excluding Extra Ord Items 4.6812.6811.8016.16
Total Adjustmentsto Net Income --0.00-
Gain( Loss)on Saleof Assets ---0.14-0.01
DPS- Common Stock Primary Issue ---1.00
Research Development ---8.59
*All figures in crores except per share values
Recommended For You
Trending Stocks
1,122.90+27.30(2.49%)
1,337.00-24.75 (-1.82%)
4,055.95-74.25 (-1.80%)